LIG1 and cancer: Since most adult cells in the human body do not replicate, or do so only sporadically (e.g., hematopoietic stem-cells), the highly proliferating cancer cells would be the primary target for hLig1 inhibitors while the side-effect on non-dividing normal cells is predicted to be minimal.